Hildebrandt, Michelle A T <br/><br/>
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2009 
 - 857-71 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.17.6297  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Carrier Proteins--genetics<br/>Class I Phosphatidylinositol 3-Kinases<br/>Esophageal Neoplasms--genetics<br/>Female<br/>Genotype<br/>Humans<br/>Male<br/>Middle Aged<br/>PTEN Phosphohydrolase--genetics<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphotransferases (Alcohol Group Acceptor)--genetics<br/>Polymorphism, Single Nucleotide<br/>Proto-Oncogene Proteins c-akt--genetics<br/>Radiotherapy<br/>Signal Transduction--genetics<br/>TOR Serine-Threonine Kinases<br/>Treatment Outcome